NOV 05, 2017 9:15 AM PST

New Drug 'Transformed' Infant Patients With Deadly Disorder

WRITTEN BY: Carmen Leitch

Spinal muscular atrophy (SMA) type 1 is a debilitating genetic disease impacting muscle development in infants. A new drug significantly improved symptoms in those patients; when treated, they were more likely to show improvement in motor function, and they were 47 percent more likely to live without needing a ventilator. The drug was so beneficial to patients in the study that it was halted early, and nusinersen was approved by the Food & Drug Administration for any individual with this disease. The results were reported in the New England Journal of Medicine and are outlined in the following video. 

"This is transformative for children with SMA," commented the lead author of the study, Richard S. Finkel, M.D., the Chief of Neurology at Nemours Children's Hospital in Orlando. "Babies with this debilitating and deadly disease were destined to have a short lifespan and limited motor function. This study shows nusinersen is life-altering for families touched by this genetic disorder."

SMA impacts around one in 11,000 births, with about 60 percent of cases being the severe type 1; milder cases occur in children and adults. Around one in 40 adults carry the mutation that causes the disease. The severe neuromuscular disorder starts any time before six months of age and causes progressive weakness in muscles. Affected infants are never able to sit up and have trouble breathing and swallowing, causing lung infections. Most of these infants don’t survive to their second birthday unless they have a feeding tube or other help from devices.  

Nusinersen is the first treatment option for SMA and acts on the SMN2 gene. A small piece of synthetic DNA, an antisense oligonucleotide (ASO) is injected into the spinal fluid directly, where spinal nerve cells absorb it. The ASO results in an increase in the synthesis of a protein that is needed for neuromotor development.

This study assessed 121 infants with SMA Type 1 who came from 31 centers in thirteen countries. Because both physicians and family members did not know whether a patient received the drug, it was a double-blind, randomized study. The researchers developed special procedures to ensure researchers interacting with patients did not know who had gotten medication through a spinal injection.

Infants with SMA type 1 showed improvement after drug treatment. / Image credit: Pixabay

Over the course of thirteen months, 41 percent of the infants treated with nusinersen showed improvement in motor function, and several began to develop motor skills like sitting, standing, kicking, head control, and rolling over. No progress was seen in untreated infants in the control group. In nusinersen-treated infants, the risk of death was 63 percent lower, and they were less likely to need permanent ventilation assistance. There were not any serious patient problems after administration of the drug, which was well-tolerated.

The FDA approved nusinersen, sold as Spinraza, after checking the interim data from the study in December 2016. After the study ended, another one began to evaluate the long-term effects of the drug on these patients. It is also being tested in individuals with milder forms of the disease as well as infants found to have it through genetic testing, but who do not yet display symptoms. There is an effort by Dr. Finkel and colleagues to add SMA to a newborn screening panel so it can be diagnosed and treated immediately.


Sources: AAAS/Eurekalert! Via Nemours Children’s Health System, NEJM

About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
SEP 27, 2020
Cell & Molecular Biology
How Spiders May Open a Path to IBS Treatment
SEP 27, 2020
How Spiders May Open a Path to IBS Treatment
Irritable bowel syndrome (IBS) is term that describes a gut disorder that causes abdominal pain, cramping, diarrhea or c ...
OCT 05, 2020
Cell & Molecular Biology
Gaining Insight Into the Connection Between Depression and Stress
OCT 05, 2020
Gaining Insight Into the Connection Between Depression and Stress
Depression is a common mental illness, and stress is known to be an environmental influence that can increase the risk o ...
OCT 17, 2020
Clinical & Molecular DX
Imaging Innovation Set to Ease the Pain of Osteoarthritis
OCT 17, 2020
Imaging Innovation Set to Ease the Pain of Osteoarthritis
In osteoarthritis, the joint cartilage that cushions bones begins to break down, causing debilitating pain and stiffness ...
NOV 01, 2020
Genetics & Genomics
A Better View of the Mechanisms Underlying Night Vision
NOV 01, 2020
A Better View of the Mechanisms Underlying Night Vision
When light levels are low, the rod cells of our eyes go to work to help us see.
NOV 09, 2020
Cell & Molecular Biology
The Science Behind Wine Fraud Prevention
NOV 09, 2020
The Science Behind Wine Fraud Prevention
Wine comes in a wide range of flavors and prices. Wine fraud, in which cheaply produced wine is passed off as the expens ...
NOV 14, 2020
Microbiology
The Structure of a Bacteriophage DNA Tube is Revealed
NOV 14, 2020
The Structure of a Bacteriophage DNA Tube is Revealed
Some viruses only infect bacteria; they care called bacteriophages or phages for short. As antibiotic-resistant bacteria ...
Loading Comments...